[go: up one dir, main page]

PE20081625A1 - Proteinas de union al antigeno del receptor a de la il-17 - Google Patents

Proteinas de union al antigeno del receptor a de la il-17

Info

Publication number
PE20081625A1
PE20081625A1 PE2007001329A PE2007001329A PE20081625A1 PE 20081625 A1 PE20081625 A1 PE 20081625A1 PE 2007001329 A PE2007001329 A PE 2007001329A PE 2007001329 A PE2007001329 A PE 2007001329A PE 20081625 A1 PE20081625 A1 PE 20081625A1
Authority
PE
Peru
Prior art keywords
antigen binding
binding proteins
seq
refers
receptor antigen
Prior art date
Application number
PE2007001329A
Other languages
English (en)
Inventor
David Fitzpatrick
Ai Ching Lim
Christopher Mehlin
Jacques Peschon
James F Smothers
Joel Tocker
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PE20081625A1 publication Critical patent/PE20081625A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)

Abstract

SE REFIERE A UN ANTICUERPO MONOCLONAL AISLADO, O FRAGMENTO DE UNION QUE SE UNE ESPECIFICAMENTE A IL-17RA (RECEPTOR A DE LA IL-17) HUMANA DE SEQ ID NO: 431, PERO NO SE UNE ESPECIFICAMENTE A UN POLIPEPTIDO QUIMERICO FORMADO POR SEQ ID NO: 434, 435 Y 436; Y COMPITE CON LA UNION CON CUALQUIERA DE LOS ANTICUERPOS AMH3/AML3, AMH20/AML20, AMH22/AML22, ENTRE OTROS. TAMBIEN SE REFIERE A POLINUCLEOTIDOS QUE LOS CODIFICAN, VECTORES DE EXPRESION, CELULAS DE ANFITRIONAS PARA SU PRODUCCION, COMPOSICIONES FARMACEUTICAS Y METODOS DE DIAGNOSTICO, SIENDO UTILES PARA EL TRATAMIENTO DE TRASTORNOS INFLAMATORIOS Y AUTOINMUNES
PE2007001329A 2006-10-02 2007-10-02 Proteinas de union al antigeno del receptor a de la il-17 PE20081625A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82788206P 2006-10-02 2006-10-02
US87307206P 2006-12-05 2006-12-05
US96989507P 2007-09-04 2007-09-04

Publications (1)

Publication Number Publication Date
PE20081625A1 true PE20081625A1 (es) 2009-01-11

Family

ID=39344834

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007001329A PE20081625A1 (es) 2006-10-02 2007-10-02 Proteinas de union al antigeno del receptor a de la il-17
PE2012000140A PE20120832A1 (es) 2006-10-02 2007-10-02 Proteinas de union al antigeno del receptor a de la il-17

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2012000140A PE20120832A1 (es) 2006-10-02 2007-10-02 Proteinas de union al antigeno del receptor a de la il-17

Country Status (30)

Country Link
US (15) US7767206B2 (es)
EP (4) EP2487188B1 (es)
JP (1) JP5013383B2 (es)
KR (2) KR101240903B1 (es)
CN (1) CN103214576B (es)
AR (1) AR063090A1 (es)
AU (2) AU2007314519C1 (es)
BR (1) BRPI0719762B8 (es)
CA (1) CA2663537C (es)
CL (1) CL2007002800A1 (es)
CR (1) CR10760A (es)
CY (5) CY1116291T1 (es)
DK (4) DK2487188T3 (es)
EA (1) EA019397B1 (es)
ES (4) ES2533352T3 (es)
HU (4) HUE032421T2 (es)
IL (3) IL197636B (es)
LT (4) LT2518085T (es)
LU (1) LUC00056I2 (es)
MX (1) MX2009003511A (es)
MY (1) MY187263A (es)
NL (1) NL300919I2 (es)
NO (2) NO344867B1 (es)
NZ (1) NZ575631A (es)
PE (2) PE20081625A1 (es)
PL (4) PL2076541T3 (es)
PT (4) PT2518085T (es)
SI (4) SI2518085T1 (es)
TW (1) TWI396694B (es)
WO (1) WO2008054603A2 (es)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03003407A (es) * 2000-10-18 2004-05-04 Immunex Corp Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17.
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
NZ579297A (en) * 2007-02-28 2012-03-30 Schering Corp Combination therapy comprising an il-23 antagonist and a cytokine antagonist for treatment of immune disorders
WO2008156709A1 (en) * 2007-06-13 2008-12-24 Amgen Inc. Il-17 heteromeric receptor complex
US20100256600A1 (en) * 2009-04-04 2010-10-07 Ferrera David A Neurovascular otw pta balloon catheter and delivery system
WO2009136976A2 (en) * 2008-02-21 2009-11-12 Amgen Inc Il-17ra-il-17rb antagonists and uses thereof
WO2010041145A2 (en) * 2008-10-07 2010-04-15 Novimmune Sa Il-17-mediated transfection methods
WO2010062857A1 (en) 2008-11-26 2010-06-03 Allergan, Inc. Klk-13 antibody inhibitor for treating dry eye
US20110223169A1 (en) * 2008-11-26 2011-09-15 Stern Michael E Il-17 antibody inhibitor for treating dry eye
US8835610B2 (en) 2009-03-05 2014-09-16 Abbvie Inc. IL-17 binding proteins
AU2010226391C1 (en) 2009-03-20 2016-11-24 Amgen Inc. Carrier immunoglobulins and uses thereof
RU2605318C2 (ru) 2009-05-05 2016-12-20 Новиммун С.А. Анти-il-17f антитела и способы их применения
WO2010142551A2 (en) * 2009-06-12 2010-12-16 Ablynx N.V. Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family
CN102648002A (zh) * 2009-10-10 2012-08-22 斯坦福大学托管董事会 Il-17家族细胞因子组合物及用途
TW201117824A (en) * 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
AU2010310545C1 (en) 2009-10-23 2015-04-30 Amgen British Columbia Anti-GCC antibody molecules and related compositions and methods
EP2523688B1 (en) * 2010-01-15 2017-10-11 Kirin-Amgen, Inc. Antibody formulation and therapeutic regimens
TWI596114B (zh) * 2010-02-24 2017-08-21 雷那特神經科學股份有限公司 拮抗劑抗-ｉｌ-７受體抗體及方法
CN102906118B (zh) 2010-05-20 2017-07-28 埃博灵克斯股份有限公司 与her3相关的生物材料
KR20130110169A (ko) 2010-09-22 2013-10-08 암젠 인크 담체 면역글로뷸린 및 이것의 용도
AR083546A1 (es) * 2010-10-25 2013-03-06 Genentech Inc Tratamiento de inflamacion gastrointestinal, soriasis y asma
KR20180129991A (ko) 2010-11-05 2018-12-05 노파르티스 아게 Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
CA3021845C (en) 2011-04-20 2022-03-29 Amgen Inc. Autoinjector apparatus
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP2734541B1 (en) * 2011-07-19 2017-09-06 The National Institute for Biotechnology in the Negev, Ltd. Novel il-17r-ecd mutants
US20140234330A1 (en) * 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
WO2014123696A1 (en) 2013-01-25 2014-08-14 Thymon, Llc Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease
WO2014143815A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
EP2968760B1 (en) 2013-03-15 2024-01-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
KR102295834B1 (ko) 2013-03-15 2021-08-30 암젠 인크 인체 윤곽 적응성을 가진 자기 주사기 장치
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
KR102074421B1 (ko) * 2013-03-29 2020-02-10 삼성전자주식회사 항 c-Met/항 EGFR 이중 특이 항체
CA2910766C (en) 2013-04-30 2020-12-15 Otitopic Inc. Dry powder formulations and methods of use
JP6255099B2 (ja) 2013-08-15 2017-12-27 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
EP3041863A4 (en) 2013-09-05 2017-08-16 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
WO2015057906A1 (en) * 2013-10-16 2015-04-23 Janssen Biotech, Inc. Cd200 receptor 1 agonists
KR102127408B1 (ko) * 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
EA201691473A1 (ru) 2014-02-21 2016-12-30 Дженентек, Инк. Биспецифические анти-il-13/il-17 антитела и их применение
CN106456751B (zh) 2014-03-31 2021-02-02 安姆根K-A有限公司 治疗指甲和头皮银屑病的方法
JP6671298B2 (ja) 2014-05-16 2020-03-25 アムジェン インコーポレイテッド Ｔｈ１及びｔｈ２細胞集団を検出するためのアッセイ
CN106573059A (zh) * 2014-08-26 2017-04-19 麒麟-安姆根有限公司 接受过抗TNF‑α抗体疗法的银屑病患者的治疗方法
CN115957326A (zh) 2014-09-10 2023-04-14 诺华股份有限公司 使用il-17拮抗剂抑制银屑病关节炎患者的结构损伤进展
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MX389663B (es) 2014-10-14 2025-03-20 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
GB201500461D0 (en) * 2015-01-12 2015-02-25 Cresendo Biolog Ltd Therapeutic molecules
WO2016123329A2 (en) 2015-01-28 2016-08-04 Genentech, Inc. Gene expression markers and treatment of multiple sclerosis
EA201792527A1 (ru) 2015-07-16 2018-06-29 Эли Лилли Энд Компани Лечение зуда
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
WO2017127468A1 (en) 2016-01-22 2017-07-27 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
MA44723A (fr) 2016-04-18 2019-02-27 Celldex Therapeutics Inc Anticorps agonistes se liant au cd40 humain et leurs utilisations
NZ786442A (en) 2016-06-14 2025-06-27 Adimab Llc Anti-coagulation factor xi antibodies
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
SG11201900200XA (en) * 2016-07-14 2019-02-27 Scholar Rock Inc Tgfb antibodies, methods, and uses
WO2018067198A1 (en) 2016-10-03 2018-04-12 The Regents Of The University Of California Inhibitory antibodies and methods of use thereof
WO2018096467A1 (en) 2016-11-28 2018-05-31 Novartis Ag Methods of treating acne using interleukin-17 (il-17) antagonists
EP3596225A1 (en) 2017-03-14 2020-01-22 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
TW201842933A (zh) 2017-05-05 2018-12-16 瑞士商諾華公司 使用il-17拮抗劑選擇性治療氣喘的方法
CN118994394A (zh) 2017-06-12 2024-11-22 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
KR102681843B1 (ko) 2017-09-22 2024-07-05 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
JP2021501752A (ja) 2017-11-02 2021-01-21 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用して腱障害を治療する方法
CN111263651B (zh) 2017-11-16 2022-06-17 安进公司 具有停顿和终点检测的自动注射器
EP3717907A1 (en) 2017-11-30 2020-10-07 Novartis AG Bcma-targeting chimeric antigen receptor, and uses thereof
EP3756689A4 (en) 2018-02-22 2022-07-27 Tokai University Educational System INHIBITOR OF IL-17A ACTIVITY AND ITS USE
CN111954719B (zh) 2018-03-26 2025-07-18 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
BR112020021271A2 (pt) 2018-04-17 2021-01-26 Celldex Therapeutics, Inc. construtos bispecíficos e anticorpos anti- cd27 e anti-pd-l1
CN112384531B (zh) 2018-06-01 2024-05-14 诺华股份有限公司 针对bcma的结合分子及其用途
US12134644B2 (en) * 2018-07-31 2024-11-05 Weiqun SHEN Anti-IL-17A antibodies and use thereof
US12473357B2 (en) 2018-09-25 2025-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of antagonists of Th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
CN113631574B (zh) 2019-01-31 2025-03-04 努玛治疗有限公司 对TNFα和IL-17A具有特异性的多特异性抗体、靶向IL-17A的抗体及其使用方法
US11332546B2 (en) 2019-05-21 2022-05-17 The Regents Of The University Of California Protease inhibitory antibodies and methods of use thereof
WO2021050563A1 (en) * 2019-09-09 2021-03-18 The Rockefeller University Antibody treatment for lesional tissue of hidradenitis suppurativa
CN114401993A (zh) * 2019-09-11 2022-04-26 博世健康爱尔兰有限公司 使用il-17ra抗体治疗非酒精性脂肪肝疾病(nafld)的方法
KR20220070244A (ko) 2019-09-25 2022-05-30 도꾜 다이가꾸 전신성 강피증 치료용 의약 조성물
MX2022003461A (es) 2019-09-26 2022-04-19 Amgen Inc Metodos de produccion de composiciones de anticuerpos.
US20220411500A1 (en) * 2019-11-18 2022-12-29 The Board Of Trustees Of The Leland Stanford Junior University Treatment of fibrosis with combined blockade of il-6 and immune checkpoint
EP4162257A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
MX2023004364A (es) 2020-10-15 2023-05-03 Amgen Inc Glucanos no emparejados relativos en metodos de produccion de anticuerpos.
MX2023005353A (es) 2020-11-06 2023-05-22 Novartis Ag Moleculas de union a cd19 y usos de las mismas.
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CA3233085A1 (en) * 2021-09-24 2023-03-30 Synergy Imt, Inc. Composition of recombinant antigen binding molecules and method of making and using thereof
MX2024003852A (es) 2021-10-05 2024-05-24 Amgen Inc Unión al receptor fc-gamma y contenido de glucanos.
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
CN119630422A (zh) 2022-05-16 2025-03-14 诺华股份有限公司 使用白细胞介素-17(il-17)拮抗剂治疗巨细胞动脉炎的方法
WO2023223263A1 (en) 2022-05-18 2023-11-23 Novartis Ag Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197525A (en) * 1961-08-07 1965-07-27 Union Oil Co Clathration process
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ES2238070T3 (es) 1989-04-21 2005-08-16 Amgen Inc. Receptor del tnf, proteina ligante del tnf y adn codante para estos.
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
DK0398327T4 (da) 1989-05-18 2013-04-15 Yeda Res & Dev Tumornekrosefaktor-bindende protein, dets oprensning og antistoffer dertil
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5703088A (en) * 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
CA2485553A1 (en) 1989-09-05 1991-03-21 Immunex Corporation Tumor necrosis factor - .alpha. and - .beta. receptors
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
JPH03127800A (ja) 1989-10-13 1991-05-30 Teijin Ltd 腫瘍壊死因子活性抑制物質
ES2103305T3 (es) 1989-11-29 1997-09-16 Amgen Boulder Inc Produccion de inhibidor de interleuquina-1 humana recombinada.
DE69022559T2 (de) 1989-12-13 1996-05-02 Yeda Res & Dev Expression des rekombinanten Tumor-Nekrosisfaktor-Bindungsproteins I (TBP-I).
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
DE4013159A1 (de) 1990-04-25 1991-10-31 Bosch Gmbh Robert Gehaeuseblock fuer ein hydraulisches bremssystem
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
WO1991017184A1 (en) 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
GB2243569A (en) 1990-05-02 1991-11-06 Andrew Langdon Brush with timer
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
ATE309376T1 (de) 1990-06-28 2005-11-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1992001002A1 (en) 1990-07-11 1992-01-23 Teijin Limited Tumor necrosis factor activity inhibitor and production thereof
US5858355A (en) 1990-12-20 1999-01-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education IRAP gene as treatment for arthritis
SG63617A1 (en) 1991-01-18 1999-03-30 Amgen Boulder Inc Methods for treating tumar necrosis factor mediated diseases
EP0575319B1 (en) 1991-03-11 1999-11-10 The University Of Georgia Research Foundation, Inc. Cloning and expression of renilla luciferase
DK0575545T3 (da) 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
EP0611302B1 (en) 1991-10-15 2000-03-29 MULLARKEY, Michael F. Receptors for treating late phase inflammatory responses
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
EP1239043A3 (en) 1992-03-30 2003-01-02 Immunex Corporation Fusion proteins comprising tumour necrosis factor receptor
DK0639079T3 (da) 1992-04-30 2000-06-13 Amgen Inc Fremgangsmåder til behandling af interleukin-1- og tumornekrosefaktor-medierede sygdomme
JPH05312248A (ja) 1992-05-08 1993-11-22 Nissan Motor Co Ltd シフトレバー装置
DE4219626A1 (de) 1992-06-16 1993-12-23 Wehling Peter Priv Doz Dr Med Methode zur Einschleusung therapeutisch relevanter Gene in Körperzellen
EP0620739A4 (en) 1992-09-15 1997-01-15 Immunex Corp Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
FI951250L (fi) 1992-09-17 1995-03-16 Amgen Boulder Inc Interleukiini-l-inhibiittorien farmaseuttiset formulaatiot
DK0672141T3 (da) 1992-10-23 2003-06-10 Immunex Corp Fremgangsmåder til fremstilling af opløselige, oligomere proteiner
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
CA2157782A1 (en) 1993-03-08 1994-09-15 Joseph C. Glorioso Gene transfer for treating a connective tissue of a mammalian host
JP3723206B2 (ja) 1993-03-19 2005-12-07 バクスイン・エス・アー ムラミルペプチドとサイトカインとを組み合わせることを特徴とするヒトに用いる治療用組成物
US6326353B1 (en) 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
FR2706772A1 (en) 1993-06-22 1994-12-30 Vacsyn Sa Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
EP0759170B1 (en) 1993-09-10 2008-07-09 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5695941A (en) * 1994-06-22 1997-12-09 The General Hospital Corporation Interaction trap systems for analysis of protein networks
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US6680057B1 (en) 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
DK0817847T4 (da) 1995-03-23 2009-10-05 Immunex Corp IL-17-receptor
EP1591529A3 (en) 1995-07-19 2005-11-09 Genetics Institute, LLC Human CLTA-8 and uses of CTLA-8-related proteins
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
NZ331163A (en) 1996-02-09 2000-07-28 Amgen Inc Composition comprising interleukin-1 inhibitor and hydrogel ester (hyaluronan) for treating inflammatory diseases
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US6406867B1 (en) * 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
AU7408998A (en) 1996-11-27 1998-06-22 Immunex Corporation Method of regulating nitric oxide production
PT1500329E (pt) 1996-12-03 2012-06-18 Amgen Fremont Inc Anticorpos humanos que se ligam especificamente ao tnf alfa humano
JP3795533B2 (ja) 1996-12-12 2006-07-12 プロルーム・リミテツド 感染性物質を検出及び同定するための方法及び装置
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
ES2333385T3 (es) 1997-09-17 2010-02-19 Human Genome Sciences, Inc. Proteina del tipo de interleuquina-17.
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
ATE388224T1 (de) 1998-03-27 2008-03-15 Prolume Ltd Luciferase, gfp fluoreszenzproteine, kodierende nukleinsaüre und ihre verwendung in der diagnose
EP2333069A3 (en) 1998-05-15 2011-09-14 Genentech, Inc. Therapeutic uses of IL-17 homologous polypeptides
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6144598A (en) * 1999-07-06 2000-11-07 Micron Technology, Inc. Method and apparatus for efficiently testing rambus memory devices
PL354987A1 (en) 1999-10-04 2004-03-22 Chiron Corporation Stabilized liquid polypeptide-containing pharmaceutical compositions
AU2001247545A1 (en) 2000-03-16 2001-09-24 Amgen Inc. Il-17 receptor like molecules and uses thereof
TWI322154B (en) 2000-03-16 2010-03-21 Amgen Inc Il-17 receptor like molecules and uses thereof
US20030180255A1 (en) 2000-08-24 2003-09-25 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
MXPA03003407A (es) 2000-10-18 2004-05-04 Immunex Corp Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17.
AU2002319402B2 (en) 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
WO2003072060A2 (en) 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
WO2004002519A1 (en) 2002-06-27 2004-01-08 Smithkline Beecham Corporation Methods of treating or preventing ibd with il-18
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
US20050282833A1 (en) * 2002-08-09 2005-12-22 Zehra Rowjee Pharmacological treatment of psoriasis
JP2006523090A (ja) 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US20050070460A1 (en) 2003-08-05 2005-03-31 3M Innovative Properties Company Infection prophylaxis using immune response modifier compounds
EP1678195A4 (en) * 2003-10-08 2008-04-23 The Feinstein Inst Medical Res METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CHRONIC LYMPHOCYTIC B-CELL LEUKEMIA
US20070184050A1 (en) 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
IL159670A0 (en) 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
SG149892A1 (en) * 2004-02-02 2009-02-27 Tanox Inc Identification of novel ige epitopes
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
WO2006065885A2 (en) 2004-12-16 2006-06-22 Linda Pollock Tool and method for organizing a vertically stacked pile of items
BRPI0608210A2 (pt) * 2005-02-14 2010-11-09 Wyeth Corp métodos de diagnóstico de um distúrbio relacionado com il-17f em um indivìduo e de seleção de compostos capazes de inibirem a ligação de il-17f em il-17r, uso de um antagonista de il-17f, composição farmacêutica, e, adjuvante de vacina
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
NZ564843A (en) 2005-08-03 2012-05-25 Immunogen Inc Immunoconjugate formulations comprising an immunoconjugate and an excipient in a buffered aqueous solution
EP1916997B1 (en) 2005-08-05 2018-04-18 Amgen Inc. Stable aqueous protein pharmaceutical formulations and their preparation
BRPI0615297A2 (pt) 2005-09-01 2011-05-17 Schering Corp antagonistas de il-23 e de il-17 para tratar doença inflamatória ocular auto-imune e seus usos
WO2007047738A1 (en) 2005-10-18 2007-04-26 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
PT3225233T (pt) 2005-11-01 2019-10-24 Wyeth Llc Solução de cloreto de sódio para reconstituição de fármacos.
EP1977763A4 (en) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd STABILIZER PREPARATION CONTAINING ANTIBODIES
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
EP2064237A2 (en) 2006-10-18 2009-06-03 ZymoGenetics, Inc. Il-17c antagonists and methods of using the same
CA2672902C (en) 2006-12-21 2012-11-27 Amgen Inc. Formulations
FR2910324B1 (fr) 2006-12-21 2009-03-06 Biomerieux Sa Nouveau medicament pour le traitement d'un cancer gastrique
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
CA2679588A1 (en) 2007-03-26 2008-10-02 Zymogenetics, Inc. Soluble il-17ra/rc fusion proteins and related methods
WO2008156709A1 (en) 2007-06-13 2008-12-24 Amgen Inc. Il-17 heteromeric receptor complex
WO2009006301A2 (en) 2007-06-29 2009-01-08 Battelle Memorial Institute Protein stabilization
AU2008289225A1 (en) 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and Fc-fusion molecules using polycations
WO2009136976A2 (en) 2008-02-21 2009-11-12 Amgen Inc Il-17ra-il-17rb antagonists and uses thereof
CN102648002A (zh) 2009-10-10 2012-08-22 斯坦福大学托管董事会 Il-17家族细胞因子组合物及用途
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
EP2523688B1 (en) 2010-01-15 2017-10-11 Kirin-Amgen, Inc. Antibody formulation and therapeutic regimens
EP3792281A1 (en) 2010-10-08 2021-03-17 Novartis AG Methods of treating psoriasis using il-17 antagonists
AR083546A1 (es) 2010-10-25 2013-03-06 Genentech Inc Tratamiento de inflamacion gastrointestinal, soriasis y asma
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
US9413463B2 (en) 2013-08-30 2016-08-09 Google Inc. Apparatus and method for efficient two-way optical communication where transmitter may interfere with receiver
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
CN106456751B (zh) 2014-03-31 2021-02-02 安姆根K-A有限公司 治疗指甲和头皮银屑病的方法
CN106573059A (zh) 2014-08-26 2017-04-19 麒麟-安姆根有限公司 接受过抗TNF‑α抗体疗法的银屑病患者的治疗方法

Also Published As

Publication number Publication date
US7767206B2 (en) 2010-08-03
CL2007002800A1 (es) 2008-05-23
HUE033216T2 (hu) 2017-11-28
SI2076541T1 (sl) 2015-05-29
US20100292442A1 (en) 2010-11-18
ES2906774T3 (es) 2022-04-20
SI3165539T1 (sl) 2022-05-31
US11180564B2 (en) 2021-11-23
PL3165539T3 (pl) 2022-04-25
KR20090088870A (ko) 2009-08-20
US7833527B2 (en) 2010-11-16
NO2020036I1 (no) 2020-10-28
SI2487188T1 (sl) 2017-07-31
US8435518B2 (en) 2013-05-07
US20080220479A1 (en) 2008-09-11
PL2518085T3 (pl) 2017-08-31
EP2518085B1 (en) 2016-12-07
LT2518085T (lt) 2017-05-10
US20110166331A1 (en) 2011-07-07
US20200362045A1 (en) 2020-11-19
CY1118994T1 (el) 2018-01-10
EP2487188A3 (en) 2012-10-31
IL197636A0 (en) 2011-08-01
TW200821326A (en) 2008-05-16
NL300919I2 (nl) 2018-04-11
US20080219979A1 (en) 2008-09-11
NO20091736L (no) 2009-06-30
CN103214576A (zh) 2013-07-24
MX2009003511A (es) 2009-06-26
PT2487188T (pt) 2017-05-04
DK2518085T3 (en) 2017-02-13
AU2010219370A1 (en) 2010-09-30
NZ575631A (en) 2012-04-27
AU2007314519C1 (en) 2013-06-06
CY2018001I1 (el) 2018-09-05
CY1116291T1 (el) 2017-02-08
PT2076541E (pt) 2015-03-31
CA2663537C (en) 2015-02-24
US20110008841A1 (en) 2011-01-13
EA019397B1 (ru) 2014-03-31
US7786284B2 (en) 2010-08-31
EA200900514A1 (ru) 2009-10-30
BRPI0719762A2 (pt) 2014-01-28
HUE032421T2 (en) 2017-09-28
EP2518085A1 (en) 2012-10-31
DK2076541T3 (en) 2015-03-30
LTPA2018003I1 (lt) 2018-02-12
HUE057611T2 (hu) 2022-05-28
PT2518085T (pt) 2017-03-13
DK2487188T3 (en) 2017-06-19
JP2010505416A (ja) 2010-02-25
CY2018001I2 (el) 2018-09-05
AU2010219370C1 (en) 2013-05-23
HUS1800005I1 (hu) 2018-07-30
AU2007314519A1 (en) 2008-05-08
LUC00056I2 (es) 2018-02-21
US20200017591A1 (en) 2020-01-16
IL251908A0 (en) 2017-06-29
MY187263A (en) 2021-09-16
US10208122B2 (en) 2019-02-19
AU2010219370B2 (en) 2011-01-27
US20240294652A1 (en) 2024-09-05
US11858999B2 (en) 2024-01-02
BRPI0719762B8 (pt) 2021-05-25
US20110081339A1 (en) 2011-04-07
US20100028345A1 (en) 2010-02-04
LTC2076541I2 (lt) 2018-09-10
PL2076541T3 (pl) 2015-07-31
CY1118845T1 (el) 2018-01-10
EP3165539A1 (en) 2017-05-10
CY1125133T1 (el) 2023-06-09
WO2008054603A9 (en) 2008-07-03
US7939070B2 (en) 2011-05-10
EP2487188B1 (en) 2017-03-08
WO2008054603A3 (en) 2008-09-25
IL197636B (en) 2018-02-28
CR10760A (es) 2009-05-27
US8790648B2 (en) 2014-07-29
NO344867B1 (no) 2020-06-08
US20120251547A1 (en) 2012-10-04
KR101240903B1 (ko) 2013-03-14
EP2487188A2 (en) 2012-08-15
US20160251443A1 (en) 2016-09-01
WO2008054603A2 (en) 2008-05-08
ES2616210T3 (es) 2017-06-09
AU2007314519B2 (en) 2012-08-16
BRPI0719762B1 (pt) 2019-08-20
TWI396694B (zh) 2013-05-21
SI2518085T1 (sl) 2017-05-31
CA2663537A1 (en) 2008-05-08
CN103214576B (zh) 2015-06-03
JP5013383B2 (ja) 2012-08-29
US9073999B2 (en) 2015-07-07
DK3165539T3 (en) 2022-02-14
US20090074758A1 (en) 2009-03-19
US20140356355A1 (en) 2014-12-04
US20080221307A1 (en) 2008-09-11
US8545842B2 (en) 2013-10-01
EP2076541A2 (en) 2009-07-08
PE20120832A1 (es) 2012-08-11
KR20120098953A (ko) 2012-09-05
PT3165539T (pt) 2022-03-18
PL2487188T3 (pl) 2017-09-29
IL228672A (en) 2017-11-30
IL228672A0 (en) 2013-12-31
LT2487188T (lt) 2017-05-10
AR063090A1 (es) 2008-12-23
ES2533352T3 (es) 2015-04-09
LUC00056I1 (es) 2017-12-20
EP3165539B1 (en) 2021-12-08
US9096673B2 (en) 2015-08-04
LT3165539T (lt) 2022-04-11
EP2076541B1 (en) 2015-02-18
ES2624921T3 (es) 2017-07-18

Similar Documents

Publication Publication Date Title
PE20081625A1 (es) Proteinas de union al antigeno del receptor a de la il-17
US20230406902A1 (en) Peptide mimotopes of claudin 18.2 and uses thereof
US12410256B2 (en) Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseases
US10150815B2 (en) Method of treating cancer with humanized anti-OX40 antibodies
US11046745B2 (en) Peptide mimotopes of the CD3 T-cell co-receptor epsilon chain and uses thereof
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
ECSP21023271A (es) Anticuerpos cd20 con función del efector y afinidad de enlace al receptor fc mejoradas
RU2558301C2 (ru) Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
CO6251325A2 (es) Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr)
CR20120087A (es) Anticuerpos del antígeno carcinoembrionario (cea)
AR080291A1 (es) Anticuerpos antagonistas anti receptor de il-7 y procedimientos
BRPI0821168B8 (pt) anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma
PE20090368A1 (es) Anticuerpos anti-igf
ECSP099683A (es) Proteinas de union incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos que se unen especificamente a cd154 y sus usos.
PE20141162A1 (es) Anticuerpos anti-il-23
PE20081501A1 (es) Polipeptidos heterologos il-17a/f y usos terapeuticos de los mismos
CN104823054A (zh) 对修饰后自体表位的抗肿瘤免疫应答
NO20074554L (no) Antigen bindende molekyler rettet mot MCSP og som har oker FC reseptor bindende affinitet og effektor funksjon
IL186948A0 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
MX340772B (es) Medios y metodos para fabricar neurotoxina altamente pura.
AR071885A1 (es) Proteinas de union al receptor de interleuquina 21
WO2020069303A1 (en) Antibodies against soluble bcma
RU2013139743A (ru) Гуманизированное моноклональное антитело, специфичное к синдекану-1
CA3220167A1 (en) Anti-trem-1 antibodies

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration